USSTOCK.TODAY
After-Market
Log in Sign up

Bank of America raises Eli Lilly price target to $1,557

Proactive +8 · ·by G4L

HIMS
HIMS Hims & Hers Health Inc
$22.94 -11.77%
View chart & analysis →
LLY +4.28% NVO +2.65% ISRG +1.71% BAC +2.29%ALNY ALNY +0.43%
  1. 1Bank of America raised its price target for Eli Lilly to $1,557 and maintained a buy rating.
  2. 2Bank of America increased its valuation multiple to 26 times Eli Lilly's projected 2028 earnings per share, excluding acquisition R&D costs.
  3. 3The optimistic peak sales scenario for Eli Lilly's brexipiprazole reaches $10 billion to $20 billion.

So what's the key point?

Bank of America raised its price target for Eli Lilly to $1,557, expecting the stock to rise further. The bank recommends buying the company because sales of its new drug are expected to be very high.

Source Proactive +8 · View original ↗

Related 3-line summaries

Palatin Technologies Prepares for Next-Generation Peptide Clinical Trials FinanceWire · 36m agoNovonesis targets supplement market to support GLP-1 users CNBC · 8h agoEli Lilly widens market cap gap with Novo Nordisk in obesity treatment competition The Motley Fool +4 · 10h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news